HemianopsiaNCT05141604
Feasibility Test of Virtual Reality Obstacle Detection for Low Vision Walking
A study testing Field expansion view in people with Hemianopsia and Homonymous Hemianopia, run by Massachusetts Eye and Ear Infirmary at 1 site in United States.
Trial summary
The investigators are developing a new test of pedestrian hazard detection in virtual reality (VR) head-mounted display (HMD) headset, which shows virtual oncoming pedestrians in 3D while subjects are walking in real-world environment, for evaluation of visual field expansion to improve mobility in people with visual… Read more about this study
- Who is it for?
- Ages 14 years and older
- Conditions the study is for
- Hemianopsia, Homonymous Hemianopia, Tunnel Vision
- What is being tested?
- Field expansion view
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteUnited States
- Study dates
- 17 May 2022to 31 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- At least 14 years of age (no upper age limit)
- In sufficiently good health to be able to complete sessions lasting 2-3 hours
- Able to understand English
- Able to give voluntary, informed consent
- Able to independently move short distances
- Binocular vision parameters within normal limits (Stereopsis ≤ 100 arc sec on any stereo test)
- Visual field loss, either peripheral field loss (<30 degrees diameter) or hemianopic field loss (blind in half of visual field)
- Better than 20/100 visual acuity in the worse eye
Who cannot join
- Patients with any self-reported physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study
- Any person with a self-reported medical history (such as pacemaker use or photosensitive epilepsy) or physical condition listed on the device manual of the Oculus / HMD system used for the experiment as a contraindication
- Any self-reported history of seizures (any type) in the last 6 months
Trial locations and contacts
1 site in 1 country.
United States1 site
Schepens Eye Research Institute
Boston, Massachusetts, 02114
About this study
Official title: Monocular Visual Confusion for Field Expansion
The investigators are developing a new test of pedestrian hazard detection in virtual reality (VR) head-mounted display (HMD) headset, which shows virtual oncoming pedestrians in 3D while subjects are walking in real-world environment, for evaluation of visual field expansion to improve mobility in people with visual field loss.
Read the detailed description
The investigators will develop a new pedestrian hazard detection test and conduct a single arm interventional clinical trial to evaluate simulated low vision assistive devices in a sample of field loss subjects. Pedestrian detection performance with and without field expansion information will be tested and compared. The study will include 1 to 4 visits (each 2 to 4 hours) depending on the number of trials and experimental conditions (e.g., with and without simulated assistive devices) the subject is comfortable completing. The time between visits may vary depending on scheduling constraints and availability. During each visit, the subject will complete a series of simulated collision avoidance trials in VR requiring the detection and natural avoidance of a colliding pedestrian (alongside non-colliding pedestrians) while physically walking through an empty corridor. The study will be considered minimal-risk since there will be no physical obstacles that present actual collision risks.
- Conditions
- Hemianopsia, Homonymous Hemianopia, Tunnel Vision, Visual Field Defect, Peripheral, Visual Field Constriction Bilateral, Visual Field Defect Homonymous Bilateral
- Being tested
- Field expansion view
- Keywords
- walking, collision, field expansion, visual field loss
- Medical subject headings
- Hemianopsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Field expansion viewOther
Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
| Study group | Role | What they receive |
|---|---|---|
| Field expansion view | Experimental | Various configurations of field expansion views will be additionally displayed on HMD Receives: Other: Field expansion view |
What is being measured
The primary outcome is the main question the study is designed to answer.
Response time
During the pedestrian detection task, average response time to the colliding pedestrian with and without prisms
Measured: Through study completion, an average of four months
Secondary outcomes (4)
Head movement range
During the pedestrian detection task, lateral and vertical head movement range to check the head scanning range
Measured: Through study completion, an average of four months
Walking speed
During the pedestrian detection task, the physical walking speed of the subject
Measured: Through study completion, an average of four months
Pedestrian detection rate
Proportion of simulated pedestrians detected (in HMD walking)
Measured: Through study completion, an average of four months
Error rate
Proportion of false alarms and missed targets to total targets
Measured: Through study completion, an average of four months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2021
- Study start17 May 2022
- Primary completion30 Mar 2025
- Study completion31 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HemianopsiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Sponsor type
- University, hospital or other
- Collaborators
- National Eye Institute (NEI)
- Responsible party
- Principal investigator, Eli Peli, Massachusetts Eye and Ear Infirmary
- Investigators
- Eli Peli, OD, MSc, Principal investigator, Senior Scientist
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05141604
- Sponsor's protocol ID
- 2021P003330
- Other IDs
- R01EY031777
- Status last verified
- Jun 2026
- First submitted
- 19 Nov 2021
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Monocular Visual Confusion for Field Expansion
- ClinicalTrials.gov ID
- NCT05141604
- Acronym / sponsor ID
- 2021P003330
- Conditions
- Hemianopsia, Homonymous Hemianopia, Tunnel Vision, Visual Field Defect, Peripheral, Visual Field Constriction Bilateral, Visual Field Defect Homonymous Bilateral
- Keywords
- walking, collision, field expansion, visual field loss
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Massachusetts Eye and Ear InfirmaryUniversity, hospital or other
- Collaborators
- National Eye Institute (NEI)
- Study start
- 17 May 2022 (actual)
- Primary completion
- 30 Mar 2025 (actual)
- Study completion
- 31 May 2027 (estimated)
- First posted
- 2 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators are developing a new test of pedestrian hazard detection in virtual reality (VR) head-mounted display (HMD) headset, which shows virtual oncoming pedestrians in 3D while subjects are walking in real-world environment, for evaluation of visual field expansion to improve mobility in people with visual field loss.
Detailed description
The investigators will develop a new pedestrian hazard detection test and conduct a single arm interventional clinical trial to evaluate simulated low vision assistive devices in a sample of field loss subjects. Pedestrian detection performance with and without field expansion information will be tested and compared. The study will include 1 to 4 visits (each 2 to 4 hours) depending on the number of trials and experimental conditions (e.g., with and without simulated assistive devices) the subject is comfortable completing. The time between visits may vary depending on scheduling constraints and availability. During each visit, the subject will complete a series of simulated collision avoidance trials in VR requiring the detection and natural avoidance of a colliding pedestrian (alongside non-colliding pedestrians) while physically walking through an empty corridor. The study will be considered minimal-risk since there will be no physical obstacles that present actual collision risks.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Field expansion view | Experimental | Other: Field expansion viewVarious configurations of field expansion views will be additionally displayed on HMD |
Who may qualify
- Ages
- 14 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (8 listed)
- At least 14 years of age (no upper age limit)
- In sufficiently good health to be able to complete sessions lasting 2-3 hours
- Able to understand English
- Able to give voluntary, informed consent
- Able to independently move short distances
Key exclusion criteria (3 listed)
- Patients with any self-reported physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study
- Any person with a self-reported medical history (such as pacemaker use or photosensitive epilepsy) or physical condition listed on the device manual of the Oculus / HMD system used for the experiment as a contraindication
- Any self-reported history of seizures (any type) in the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Field expansion viewOverlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision | Other | Field expansion view |
Primary outcome
Response time
Time frame: Through study completion, an average of four months
During the pedestrian detection task, average response time to the colliding pedestrian with and without prisms
4 secondary outcomes
Head movement range
Time frame: Through study completion, an average of four months
Walking speed
Time frame: Through study completion, an average of four months
Pedestrian detection rate
Time frame: Through study completion, an average of four months
Error rate
Time frame: Through study completion, an average of four months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Hemianopsia
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Not yet recruiting
Multisensory Rehabilitation of Vision Loss After Cortical Damage
Cortical Blindness
Recruiting
Ameliorating Stroke-induced Hemianopia Via Multisensory Training
Hemianopia, Homonymous, Cortical Blindness, Unspecified Side of Brain
Active, not recruiting
Statistical Learning as a Novel Intervention for Cortical Blindness
Stroke, Ischemic, Hemianopia, Homonymous
Not yet recruitingObservational study
Anatomical and Functional Predictions of Blindsight Capabilities in Patients With Lateral Hemianopsia
Homonymous Hemianopia, Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eli Peli, OD, MSc principal investigator
Senior Scientist
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Field expansion view in people with Hemianopsia and Homonymous Hemianopia, run by Massachusetts Eye and Ear Infirmary at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Response time (time frame: Through study completion, an average of four months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.